(搜尋結果 2426 項結果)
排序:
Acute Heart Failure – Pipeline Review, H2 2012
2012/08/31
Acute Heart Failure – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Acute Heart Failure - Pipeline Review, H2 2012', provides an overvi.. more USD 2,000
Lymphoma – Pipeline Review, H2 2012
2012/08/31
Lymphoma – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Lymphoma - Pipeline Review, H2 2012', provides an overview of the Lymphoma the.. more USD 2,500
Retail Clinics - 2012 Yearbook
2012/08/06
Retail Clinics - 2012 Yearbook
Summary
GBI Research’s new report, “Retail Clinics - 2012 Yearbook”, provides insights into the US retail clinic mark.. more USD 3,500
Global 56 Market in the 4 Industry 2011-2015
2012/07/20
TechNavio's analysts forecast the Global Business Intelligence market in the Healthcare industry to grow at a CAGR of 10.12 percent over the period 20.. more USD 1,500
Clinical Development and Trial Design - Developing a Coherent Approach From Beginning to End
2012/06/15
Clinical Development and Trial Design - Developing a Coherent Approach From Beginning to End
Summary
A good clinical development plan will ensure su.. more USD 3,900
Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar
2012/06/12
Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosi.. more USD 3,500
Central & Eastern Europe Pharmaceuticals & Healthcare Reports
2012/05/22
The pharmaceutical market of Central & Eastern Europe (CEE) is expected to reach US$104.2 billion at retail prices by 2016. The market is expected.. more Pricing and Reimbursement in Brazil - Health Technology Assessment (HTA) Studies to Facilitate Setting of Ceiling Prices for New Drugs
2012/05/18 | 新興國家
Pricing and Reimbursement in Brazil - Health Technology Assessment (HTA) Studies to Facilitate Setting of Ceiling Prices for New Drugs
Summary
GBI R.. more USD 3,500
Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
2012/05/18
Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Gro.. more USD 3,500
Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs through the DLO’s Seven Nosologies Program
2012/04/02 | 歐洲
Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs through the DLO’s Seven Nosologies Program
Summary
.. more USD 3,500